| Display title | Chemistry:Motavizumab |
| Default sort key | Motavizumab |
| Page length (in bytes) | 3,728 |
| Namespace ID | 3022 |
| Namespace | Chemistry |
| Page ID | 767040 |
| Page content language | en - English |
| Page content model | wikitext |
| Indexing by robots | Allowed |
| Number of redirects to this page | 0 |
| Counted as a content page | Yes |
| HandWiki item ID | None |
| Edit | Allow all users (infinite) |
| Move | Allow all users (infinite) |
| Page creator | imported>Dennis Ross |
| Date of page creation | 03:50, 6 February 2024 |
| Latest editor | imported>Dennis Ross |
| Date of latest edit | 03:50, 6 February 2024 |
| Total number of edits | 1 |
| Recent number of edits (within past 90 days) | 0 |
| Recent number of distinct authors | 0 |
Description | Content |
Article description: (description)
This attribute controls the content of the description and og:description elements. | Motavizumab (proposed INN, trade name Numax) is a humanized monoclonal antibody. It is being investigated by MedImmune (today a subsidiary of AstraZeneca) for the prevention of respiratory syncytial virus infection in high-risk infants. (As of September 2009), it is undergoing Phase II and III clinical... |
